Dejan Jakimovski

List of Publications by Year in Descending Order

97 papers	1,166 citations	19 h-index	30 g-index
108 ext. papers	1,629 ext. citations	4.3 avg, IF	4.91 L-index

#	Paper	IF	Citations
97	Patient-Reported Outcome Severity and Emotional Salience Network Disruption in Multiple Sclerosis.. *Brain Imaging and Behavior*, **2022**, 1	4.1	0
96	Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis.. *European Radiology*, **2022**, 1	8	
95	Persistent spinal cord enhancement in longitudinal extensive transverse myelitis associated with α1-antitrypisn deficiency: a case report. *Neuroimmunology Reports*, **2022**, 100090		
94	COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections. *Vaccines*, **2022**, 10, 695	5.3	1
93	A prospective study to validate the expanded timed get-up-and-go in a population with multiple sclerosis.. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2022**, 8, 20552173221099186	2	
92	Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2022**, 103906	4	
91	Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.. *Multiple Sclerosis and Related Disorders*, **2021**, 57, 103406	4	2
90	Functional network dynamics and decreased conscientiousness in multiple sclerosis. *Journal of Neurology*, **2021**, 1	5.5	1
89	Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. *Journal of Neurology*, **2021**, 268, 4796-4808	5.5	1
88	The cholesterol autoxidation products, 7-ketocholesterol and 7β-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2021**, 50, 102864	4	1
87	Staging and stratifying cognitive dysfunction in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 13524585211011390	5	
86	Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. *Journal of Neuroimaging*, **2021**, 31, 995-1002	2.8	1
85	Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient. *Multiple Sclerosis Journal*, **2021**, 27, 2291-2292	5	5
84	Recovery of cognitive function after relapse in multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 71-78	5	19
83	Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption. *Journal of Neurology*, **2021**, 268, 169-177	5.5	4
82	Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross-Sectional Structural MRI Study. *Journal of Magnetic Resonance Imaging*, **2021**, 53, 731-739	5.6	3
81	Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2021**, 47, 102653	4	4

80	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. *NeuroImage: Clinical*, **2021**, 32, 102802	5.3	0
79	Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. *NeuroImage: Clinical*, **2021**, 29, 102554	5.3	1
78	Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI. *NeuroImage: Clinical*, **2021**, 31, 102705	5.3	2
77	Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. *Journal of Neurology*, **2021**, 268, 2578-2588	5.5	3
76	Considering patient age when treating multiple sclerosis across the adult lifespan. *Expert Review of Neurotherapeutics*, **2021**, 21, 353-364	4.3	0
75	Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis. *Journal of the Neurological Sciences*, **2021**, 427, 117552	3.2	2
74	Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives. *Neurodegenerative Disease Management*, **2021**, 11, 329-340	2.8	1
73	Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient. *Acta Neurologica Belgica*, **2021**, 1	1.5	1
72	DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis. *NeuroImage: Clinical*, **2021**, 30, 102652	5.3	2
71	Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.. *CNS Drugs*, **2021**, 36, 45	6.7	2
70	Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. *Journal of Neuroimaging*, **2020**, 30, 342-350	2.8	7
69	Functional Connectivity and Structural Disruption in the Default-Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. *Journal of Neuroimaging*, **2020**, 30, 523-530	2.8	8
68	Tonsillectomy in multiple sclerosis patients: Retrospective, case-controlled, exploratory study. *Multiple Sclerosis and Related Disorders*, **2020**, 42, 102131	4	2
67	Dietary inflammatory index and risk of multiple sclerosis: Findings from a large population-based incident case-control study. *Clinical Nutrition*, **2020**, 39, 3402-3407	5.9	17
66	Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls. *Neurobiology of Aging*, **2020**, 90, 84-92	5.6	9
65	Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. *Vaccines*, **2020**, 8,	5.3	18
64	Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. *Fluids and Barriers of the CNS*, **2020**, 17, 9	7	1
63	Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	12

62	Magnetic Resonance Imaging and Analysis in Multiple Sclerosis. *Current Clinical Neurology*, **2020**, 109-136	0.1	2
61	Demographic, Clinical and Biochemical Characteristics of Pediatric Obesity: Interim Analysis of a Larger Prospective Study. *Folia Medica*, **2020**, 62, 746-752	0.5	
60	Differential Diagnosis of Cognitive Decline in Elderly Individuals With Multiple Sclerosis. *Cognitive and Behavioral Neurology*, **2020**, 33, 294-300	1.6	1
59	Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. *Journal of Vascular Research*, **2020**, 57, 16-23	1.9	5
58	A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. *Journal of Neurology*, **2020**, 267, 802-811	5.5	6
57	Late onset multiple sclerosis is associated with more severe ventricle expansion. *Multiple Sclerosis and Related Disorders*, **2020**, 46, 102588	4	5
56	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. *Journal of Clinical Lipidology*, **2020**, 14, 675-684.e2	4.9	4
55	Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis. *Frontiers in Neurology*, **2020**, 11, 553616	4.1	1
54	Long-term drug treatment in multiple sclerosis: safety success and concerns. *Expert Opinion on Drug Safety*, **2020**, 19, 1121-1142	4.1	5
53	Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. *Frontiers in Neurology*, **2020**, 11, 700	4.1	3
52	Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2020**, 45, 102389	4	8
51	Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. *American Journal of Neuroradiology*, **2020**, 41, 1577-1583	4.4	2
50	Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. *Diagnostics*, **2020**, 10,	3.8	1
49	High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. *Journal of the Neurological Sciences*, **2020**, 418, 117120	3.2	3
48	Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. *Multiple Sclerosis Journal*, **2020**, 26, 201-209	5	18
47	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. *Multiple Sclerosis Journal*, **2020**, 26, 322-332	5	14
46	Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 1433-1436	5	5
45	Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. *Multiple Sclerosis Journal*, **2020**, 26, 1670-1681	5	33

44	Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up. *European Journal of Neurology*, **2020**, 27, 188-e4	6	12
43	Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis. *European Journal of Neurology*, **2020**, 27, 235-243	6	6
42	MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. *Expert Review of Neurotherapeutics*, **2020**, 20, 821-834	4.3	6
41	Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. *Human Brain Mapping*, **2019**, 40, 5231-5241	5.9	20
40	Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. *Radiology*, **2019**, 293, 424-433	20.5	18
39	Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders. *CNS Drugs*, **2019**, 33, 1073-1086	6.7	7
38	Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. *Journal of Lipid Research*, **2019**, 60, 1190-1198	6.3	19
37	No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years. *BMC Neurology*, **2019**, 19, 121	3.1	1
36	Aging and Brain Atrophy in Multiple Sclerosis. *Journal of Neuroimaging*, **2019**, 29, 527-535	2.8	16
35	Epidemiology and treatment of multiple sclerosis in elderly populations. *Nature Reviews Neurology*, **2019**, 15, 329-342	15	99
34	Vascular aspects of multiple sclerosis: emphasis on perfusion and cardiovascular comorbidities. *Expert Review of Neurotherapeutics*, **2019**, 19, 445-458	4.3	17
33	Cognitive Profiles of Aging in Multiple Sclerosis. *Frontiers in Aging Neuroscience*, **2019**, 11, 105	5.3	24
32	Coagulation Pathways in Neurological Diseases: Multiple Sclerosis. *Frontiers in Neurology*, **2019**, 10, 409	4.1	24
31	Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. *European Journal of Neurology*, **2019**, 26, 87-e8	6	48
30	Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?. *Clinical Autonomic Research*, **2019**, 29, 329-338	4.3	3
29	Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition. *Multiple Sclerosis Journal*, **2019**, 25, 1243-1254	5	21
28	Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. *Neurodegenerative Disease Management*, **2019**, 9, 149-172	2.8	30
27	Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. *Annals of Clinical and Translational Neurology*, **2019**, 6, 1757-1770	5.3	39

26	High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: A fatigue-metabolism nexus?. *Journal of Clinical Lipidology*, **2019**, 13, 654-663.e1	4.9	9
25	Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study. *Current Neurovascular Research*, **2019**, 16, 215-223	1.8	4
24	The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to imaging. *Neural Regeneration Research*, **2019**, 14, 373-386	4.5	74
23	Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. *Journal of Neurology*, **2019**, 266, 866-875	5.5	20
22	Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives. *Patient Related Outcome Measures*, **2019**, 10, 373-384	2.9	3
21	Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?. *Thrombosis and Haemostasis*, **2019**, 119, 175-178	7	5
20	Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures. *Multiple Sclerosis and Related Disorders*, **2019**, 27, 298-304	4	10
19	Plasma levels of soluble NCAM in multiple sclerosis. *Journal of the Neurological Sciences*, **2019**, 396, 36-41	3.2	10
18	Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. *Journal of Alternative and Complementary Medicine*, **2018**, 24, 596-602	2.4	14
17	Interferon for Multiple Sclerosis. *Cold Spring Harbor Perspectives in Medicine*, **2018**, 8,	5.4	57
16	Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients. *Multiple Sclerosis and Related Disorders*, **2018**, 25, 37-42	4	8
15	White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. *Human Brain Mapping*, **2018**, 39, 3682-3690	5.9	16
14	Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis. *American Journal of Neuroradiology*, **2018**, 39, 1703-1709	4.4	12
13	Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. *Journal of the Neurological Sciences*, **2018**, 393, 128-134	3.2	20
12	Neck Vessel Cross-Sectional Area Measured with MRI: Scan-Rescan Reproducibility for Longitudinal Evaluations. *Journal of Neuroimaging*, **2018**, 28, 48-56	2.8	5
11	Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis. *American Journal of Neuroradiology*, **2018**, 39, 123-130	4.4	21
10	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. *American Journal of Neuroradiology*, **2018**, 39, 2237-2242	4.4	18
9	Jugular Venous Flow Quantification Using Doppler Sonography. *Ultrasound in Medicine and Biology*, **2018**, 44, 1762-1769	3.5	5

8	Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. *Journal of Neuroimaging*, **2018**, 28, 490-495	2.8	35
7	Hemostasis biomarkers in multiple sclerosis. *European Journal of Neurology*, **2018**, 25, 1169-1176	6	19
6	Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. *American Journal of Neuroradiology*, **2018**, 39, 1480-1486	4.4	11
5	Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis. *Current Neurovascular Research*, **2017**, 14, 266-273	1.8	4
4	Global and regional brain atrophy is associated with low or retrograde facial vein flow in multiple sclerosis. *Veins and Lymphatics*, **2017**, 6,	1.3	2
3	Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. *Expert Opinion on Biological Therapy*, **2017**, 17, 1163-1172	5.4	20
2	Use of natalizumab in multiple sclerosis: current perspectives. *Expert Opinion on Biological Therapy*, **2016**, 16, 1151-62	5.4	11
1	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. *Expert Review of Neurotherapeutics*, **2016**, 16, 777-93	4.3	94